Logo

American Heart Association

  8
  0


Final ID: MDP964

Identification of Obstructive and Non-Obstructive Hypertrophic Cardiomyopathy Patients Using Natural Language Processing in a Large Integrated Healthcare System

Abstract Body (Do not enter title and authors here):
Introduction Accurately identifying and characterizing patients with hypertrophic cardiomyopathy (HCM) is critical for population management and care optimization.

Research Question To develop natural language processing (NLP) algorithms to identify and characterize obstructive (oHCM) and non-obstructive (nHCM) HCM patients directly from echocardiograms, and to compare with the presence or absence of HCM-related diagnosis codes.

Methods We developed and validated NLP algorithms to identify HCM from all adult (age≥18yrs) echocardiograms performed from 2010-2019 in Kaiser Permanente Northern CA (KPNC), capturing measures of any HCM, HCM subtype, hypertrophy subtype, septal and posterior LV wall thickness, resting and stress/Valsalva LVOT gradients, and systolic anterior motion. We developed a rules-based algorithm (following AHA/ACC criteria) to classify patients as having HCM, including oHCM or nHCM subtypes, and possible HCM (defined as wall thickness ≥2cm without other criteria meeting an HCM definition). We evaluated the presence of HCM-related ICD-9/10 diagnosis codes among patients classified as HCM/non-HCM from echocardiograms using NLP, and linked baseline demographics and clinical parameters from our integrated electronic medical record.

Results Among 472,405 adults with echocardiograms, we identified 2,892 patients with HCM based upon NLP-derived measures (all NLP measures achieved >95% positive predictive value and >95% negative predictive value), including 1,585 (55%) with oHCM, 1,145 (40%) with nHCM, and 162 (6%) which could not be classified (Figure). Among those 2,892 patients, 1,283 did not have any associated HCM ICD-9/10 diagnosis codes (Table). Among 469,513 patients with no identified HCM from NLP-based algorithms, HCM ICD-9/10 diagnosis codes existed in 1,567 patients (Table). We also identified 4,593 patients with possible HCM by NLP, only 4.5% of whom had an associated HCM code. Among confirmed HCM patients by NLP, oHCM patients were slightly older (66 vs 61 yrs), more likely female (53% vs 43%), had similar mean septal wall thickness (1.7cm vs 1.7cm), but were more likely to have a septal hypertrophy subtype (46% vs 28%) compared to nHCM patients.

Conclusions Echocardiogram-based NLP methods can improve the identification of and care for HCM patients. Many patients with possible HCM may be underdiagnosed, representing an opportunity for quality improvement.
  • Sheridan, Ann  ( Kaiser Permanente Northern California , Oakland , California , United States )
  • Liu, Jane  ( Kaiser Permanente Northern California , Oakland , California , United States )
  • Tabada, Grace  ( Kaiser Permanente Northern California , Oakland , California , United States )
  • Tan, Thida  ( Kaiser Permanente Northern California , Oakland , California , United States )
  • Dubey, Anand  ( Bristol Myers Squibb , Miami , Florida , United States )
  • Lucas, Matthew  ( Bristol Myers Squibb , Miami , Florida , United States )
  • Zhong, Yue  ( Bristol Myers Squibb , Miami , Florida , United States )
  • Okano, Gary  ( Bristol Myers Squibb , Thousand Oaks , California , United States )
  • Solomon, Matthew  ( Kaiser Permanente Northern California , Oakland , California , United States )
  • Author Disclosures:
    Ann Sheridan: DO NOT have relevant financial relationships | Jane Liu: DO NOT have relevant financial relationships | Grace Tabada: DO NOT have relevant financial relationships | Thida Tan: DO NOT have relevant financial relationships | Anand Dubey: DO have relevant financial relationships ; Employee:BMS:Active (exists now) ; Individual Stocks/Stock Options:BMS:Active (exists now) | Matthew Lucas: No Answer | Yue Zhong: No Answer | Gary Okano: No Answer | Matthew Solomon: DO have relevant financial relationships ; Research Funding (PI or named investigator):Bristol Myers Squibb:Active (exists now)
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Advances in Identification and Management of Hypertrophic Cardiomyopathy

Sunday, 11/17/2024 , 09:30AM - 10:45AM

Moderated Digital Poster Session

More abstracts on this topic:
Cardiac Myosin Inhibitors Improve Hemodynamics and Symptom Burden in Symptomatic Hypertrophic Cardiomyopathy: An Updated Meta-Analysis

Raheel Mahad, Franco Veronica, Hasan Ayesha, Vallakati Ajay, Goyal Akash, Smith Sakima, Patel Vaiibhav, Kahwash Rami, Lampert Brent, Bole Indra, Foreman Beth, Haas Garrie

AI-enhanced Electrocardiographic Evaluation of Left Ventricular Ejection Fraction and Outflow Tract Gradient in Hypertrophic Cardiomyopathy

Sangha Veer, Aminorroaya Arya, Dhingra Lovedeep, Pedroso Aline, Oikonomou Evangelos, Khera Rohan

More abstracts from these authors:
Real-world Long-term Effectiveness of Mavacamten in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy: a Multicenter Observational Study (MARVEL-HCM)

Abraham Theodore, Kim Mi-ok, Schuler Patricia, Dubey Anand, Alsidawi Said, Martinez Matthew, Wheeler Matthew, Roehl Kaitlin, Patel Ruchi, Soutar Marybeth, Herry Morgane, Wang Annie

Variation in Prevalence, Treatment, and Outcomes in Heart Failure with Improved Ejection Fraction by Race and Ethnicity

Chang Alex, Vasti Elena, Sandhu Alexander, Go Alan, Adatya Sirtaz, Bhatt Ankeet, Lee Keane, Parikh Rishi, Ambrosy Andrew, Tan Thida, Hamilton Steven, Pabon Porras Maria, Vardeny Orly, Ku Ivy

You have to be authorized to contact abstract author. Please, Login
Not Available